NA-831 was efficacious in lowering depressive and anxious symptoms in patients who received the treatment for six weeks.

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key focus areas.